Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2018—Quantimetrix announced the launch of its Dipper POCT Single-Use Liquid Urinalysis Dipstick Control for use in a variety of testing environments, including central labs, reference labs, nursing stations, and doctors’ offices.
July 2018—Meridian Life Science launched TruBlock Ready, a broad-acting HAMA blocker that is ready to use within a single dilution step.
July 2018—Binding Site’s Immunologicals Group has added three parainfluenza virus antigens for in vitro diagnostic manufacturing and research applications. The Parainfluenza Virus Type 1, Type 2, and Type 3 antigens have been designed for use in solid phase enzyme immunoassay test procedures, especially ELISAs.
July 2018—Fujirebio has entered into an agreement with Janssen Pharmaceuticals to develop and commercialize an amyloid β 42/40 ratio assay. The assay will run on the Lumipulse series
July 2018—PLUGS (Patient-centered Laboratory Utilization Guidance Services) and Metis Genetics announced a partnership to provide case review services via GeneTestAdvisor, a case management solution for genetic testing to support health care systems and insurance payers in effectively administering their genetic testing caseload.
June 2018—Sakura Finetek USA launched its Tissue-Tek Prisma Plus Automated Slide Stainer, which has a throughput of 530 slides per hour.
June 2018—Beckman Coulter Diagnostics announced it received the CE mark for its DxH 520 hematology analyzer, a 5-part differential, closed-tube analyzer for small-volume laboratories.
June 2018—EKF Diagnostics announced FDA 510(k) clearance and CLIA waiver for its DiaSpect handheld hemoglobin analyzer.
June 2018—Curetis has been granted de novo clearance by the FDA to market the Unyvero System and Lower Respiratory Tract Infection Application Cartridge in the U.S.
June 2018—MDxHealth announced that its ConfirmMDx is included in the 2018 European Association of Urology guidelines. Inclusion in the guidelines will facilitate adoption of the test in EU member state-specific guidelines, and the company will pursue CE marking of the test.
